Evidence map›Paper›PMID 26863573›Full record

ArticleOncotarget2016

Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology.

James Che, Victor Yu, Manjima Dhar, Corinne Renier, Melissa Matsumoto, Kyra Heirich, Edward B Garon, Jonathan Goldman, Jianyu Rao, George W Sledge and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed.

  1. Article
  2. Plasmonic-Hydrogel Hybrid Biomaterials Via In Situ Seeded Growth.Angewandte Chemie (International ed. in English) · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Spatiotemporally controlled microvortices provide advanced microfluidic components.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

James CheDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Victor YuDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Manjima DharDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Corinne RenierVortex Biosciences, Menlo Park, California, USA.
Melissa MatsumotoDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Kyra HeirichDepartment of Surgery, Stanford University School of Medicine, Stanford, California, USA.
Edward B GaronDepartment of Hematology & Oncology, UCLA Medical Center, Los Angeles, California, USA.
Jonathan GoldmanDepartment of Hematology & Oncology, UCLA Medical Center, Los Angeles, California, USA.
Jianyu RaoDepartment of Pathology & Laboratory Medicine, UCLA Medical Center, Los Angeles, California, USA.
George W SledgeStanford Women's Cancer Center, Stanford, California, USA.
Mark D PegramStanford Women's Cancer Center, Stanford, California, USA.
Shruti ShethStanford Women's Cancer Center, Stanford, California, USA.
Stefanie S JeffreyDepartment of Surgery, Stanford University School of Medicine, Stanford, California, USA.
Rajan P KulkarniDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Elodie SollierDepartment of Bioengineering, University of California, Los Angeles, California, USA.
Dino Di CarloDepartment of Bioengineering, University of California, Los Angeles, California, USA.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA Clinical and Translational Science InstituteKL2TR000122 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$4.5M
Isolating circulating tumor cells using a centrifuge on a chipR33CA177456 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DI CARLO, DINO · 2013 to 2015
$719k
NCATS NIH HHS KL2 TR000122NCI NIH HHS P30 CA016042NCI NIH HHS R33 CA177456
6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are emerging as rare but clinically significant non-invasive cellular biomarkers for cancer patient prognosis, treatment selection, and treatment monitoring. Current CTC isolation approaches, such as immunoaffinity, filtration, or size-based techniques, are often limited by throughput, purity, large output volumes, or inability to obtain viable cells for downstream analysis. For all technologies, traditional immunofluorescent staining alone has been employed to distinguish and confirm the presence of isolated CTCs among contaminating blood cells, although cells isolated by size may express vastly different phenotypes. Consequently, CTC definitions have been non-trivial, researcher-dependent, and evolving. Here we describe a complete set of objective criteria, leveraging well-established cytomorphological features of malignancy, by which we identify large CTCs. We apply the criteria to CTCs enriched from stage IV lung and breast cancer patient blood samples using the High Throughput Vortex Chip (Vortex HT), an improved microfluidic technology for the label-free, size-based enrichment and concentration of rare cells. We achieve improved capture efficiency (up to 83%), high speed of processing (8 mL/min of 10x diluted blood, or 800 μL/min of whole blood), and high purity (avg. background of 28.8±23.6 white blood cells per mL of whole blood). We show markedly improved performance of CTC capture (84% positive test rate) in comparison to previous Vortex designs and the current FDA-approved gold standard CellSearch assay. The results demonstrate the ability to quickly collect viable and pure populations of abnormal large circulating cells unbiased by molecular characteristics, which helps uncover further heterogeneity in these cells.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsFemaleHigh-Throughput Screening AssaysHumansLung NeoplasmsMaleMicrofluidic Analytical TechniquesMiddle AgedNeoplastic Cells, Circulatingcirculating tumor cellsimmunofluorescent stainingrare cell enrichmentsize based cell isolationVortex

Identifiers

PMID26863573
PMCPMC4914319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.